Abstract
BackgroundIguratimod (IGU) is newly synthetic DMARDs and under clinical use to the rheumatoid arthritis (RA) patients from 2012 in Japan.ObjectivesWe examined the effects of the IGU therapies for RA patients...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
